PALO ALTO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that long-term efficacy and safety data in patients with ATTR-CM from the open-label extension (OLE) trial of ATTRibute-CM, its Phase 3 study of acoramidis, will be shared in a late-breaking oral presentation at the American College of Cardiology (ACC) Annual Scientific Sessions & Expo, taking place in New Orleans, Louisiana on March 28-30, 2026. Additionally, BridgeBio was selected to share three posters on additional OLE data and real-world survey findings.

Late-Breaking Oral Presentation:
Long-Term Survival Benefits and Disease Stabilization with Acoramidis in Patients with ATTR-CM
Presenter: Prem Soman, M.D., Ph.D., University of Pittsburgh School of Medicine
Date: Monday, March 30 at 2:33 pm CT

Posters:
Long-Term Benefits With Acoramidis on Serum Transthyretin Concentrations and Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS) Score in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Presenter: Sarah Cuddy, M.D., Brigham and Women's Hospital
Date: Saturday, March 28 at 12:30 pm CT

Association Between Early Increase in sTTR with Acoramidis and Long-term Effects on Heart Failure – Related Health Status in ATTR-CM: Results from ATTRibute-CM
Presenter: Jan Griffin, M.D., Medical University of South Carolina
Date: Saturday, March 28 at 3:30 pm CT

Treatment Patterns and Preferences in ATTR-CM in the United States: Results from a Real-World Survey
Presenter: Jill Waldron, MSN, GNP, MS, University of Utah
Date: Monday, March 30 at 9:30 am CT